NEOG
Neogen Corporation
NEOG has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
NEOG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
NEOG's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NEOG PE Valuation
NEOG has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
NEOG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
NEOG has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
NEOG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.34 | — |
| Q3 2026 | -$0.26 | +$4.54 |
| Q2 2026 | -$0.04 | +$4.99 |
| Q1 2026 | -$2.80 | -$0.57 |
| Q4 2025 | -$2.77 | -$0.58 |
| Q3 2025 | -$4.80 | -$4.69 |
| Q2 2025 | -$5.03 | -$4.99 |
| Q1 2025 | -$2.23 | -22400% |
| Q4 2024 | -$2.19 | -3750% |
NEOG is still losing money, but far less than before: $0.26 per share over the past year, against $5.03 at its worst in mid-2025.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over NEOG on earnings quality, reporting a profit while its opponent remains loss making.
NEOG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $222.8M | +6.5% |
| Q2 2026 | $225.3M | -0.1% |
| Q1 2026 | $211.2M | -4.4% |
| Q4 2025 | $224.7M | -2.8% |
| Q3 2025 | $209.2M | -3.6% |
| Q2 2025 | $225.5M | -4.8% |
| Q1 2025 | $221M | -3.4% |
| Q4 2024 | $231.3M | +0.7% |
NEOG's revenue grew through 2023 and has held roughly level since: $223M last quarter, up 6.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.8% | +6.9 points |
| Q2 2026 | 1.4% | +273 points |
| Q1 2026 | -1.6% | -4 points |
| Q4 2025 | -2.4% | +195 points |
| Q3 2025 | -7.7% | -8.7 points |
| Q2 2025 | -271% | -277 points |
| Q1 2025 | 2.5% | -2.8 points |
| Q4 2024 | -198% | -204 points |
NEOG's operating margin was −0.8% last quarter, up 6.9 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over NEOG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over NEOG on profitability, with a higher operating margin.
NEOG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.7M | +$17.8M |
| Q2 2026 | $26.2M | +6353% |
| Q1 2026 | $11.1M | +$24.6M |
| Q4 2025 | $7.8M | -66% |
| Q3 2025 | -$13.1M | +$43.2M |
| Q2 2025 | $406K | -84% |
| Q1 2025 | -$13.5M | +$48.8M |
| Q4 2024 | $23.1M | +$31.8M |
NEOG has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
NEOG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +600K shares |
| 1 year | +0.4% | +765K shares |
| 3 years | +0.6% | +1.3M shares |
| 5 years | +102% | +110M shares |
| Available history | +106% | +112M shares |
NEOG has 218M diluted shares, about the same as a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over NEOG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
NEOG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 12.7x | High |
| Q2 2026 | 6.4x | High |
| Q3 2024 | 4.8x | High |
| Q2 2024 | 4.1x | High |
| Q1 2024 | 3.9x | Elevated |
| Q4 2023 | 3.7x | Elevated |
| Q3 2023 | 4.4x | High |
| Q2 2023 | 5.7x | High |
NEOG's net debt is about 13 years of its operating earnings (EBITDA), up from 3.9 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over NEOG on leverage, with a lower net debt burden relative to earnings.
NEOG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.8 | Neutral |
| Stochastic | 25.0 | Neutral |
NEOG's weekly RSI is 51 (neutral) and its Stochastic is 25 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
NEOG PE vs Healthcare Sector
| Metric | NEOG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NEOG has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NEOG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.1 | 7.3% below |
| 20 week MA | $11.5 | 2.9% below |
| 50 week MA | $10.1 | 11% above |
| 100 week MA | $8.62 | 30% above |
| 200 week MA | $12.9 | 13% below |
NEOG has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
NEOG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.5 | $40.5 | +24% |
| 2021 | $40.5 | $44.4 | +9.7% |
| 2022 | $44.4 | $14.9 | -67% |
| 2023 | $14.9 | $20.1 | +35% |
| 2024 | $20.1 | $12.4 | -38% |
| 2025 | $12.4 | $7.13 | -43% |
| 2026 YTD | $7.13 | $11.2 | +57% |
NEOG has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.